natgillin/translations-raw huggingface dataset:
In patients with polyarticular juvenile idiopathic arthritis who were 4 to 17 years, anti-adalimumab antibodies were identified in 15.8% (27/171) of patients treated with adalimumab.
Med bolniki s poliartikularnim juvenilnim idiopatskim artritisom, ki so bili stari od 4 do 17 let, so protitelesa proti adalimumabu ugotovili pri 15,8 % (27/171) tistih, ki so dobivali adalimumab.
In patients with pre-existing anaemia, leucopenia, and/or thrombocytopenia as well as in patients with impaired bone marrowfunction or those at risk of bone marrowsuppression, the risk of haematological disorders is increased.
Tveganje za pojav hematoloških motenj je večje pri bolnikih z obstoječo anemijo, levkopenijo in/ali trombocitopenijo, pri bolnikih z okvarjenim delovanjem kostnega mozga in tistih s tveganjem za supresijo kostnega mozga.
In patients with pre-existing or recent onset of demyelinating disorders, the benefits and risks of anti-TNF treatment should be carefully considered before initiation of Inflectra therapy.
Pri bolnikih z obstoječo ali nedavno nastalo demielinizirajočo boleznijo morate pred uvedbo terapije z zdravilom Inflectra skrbno pretehtati razmerje med tveganji in koristmi anti-TNF zdravljenja za bolnika.
In patients with pre-existing or recent onset of demyelinating disorders, the benefits and risks of anti-TNF treatment should be carefully considered before initiation of Remsima therapy.
Pri bolnikih z obstoječo ali nedavno nastalo demielinizirajočo boleznijo morate pred uvedbo terapije z zdravilom Remsima skrbno pretehtati razmerje med tveganji in koristmi anti-TNF zdravljenja za bolnika.
In patients with pre-existing or recent onset of demyelinating disorders, the benefits and risks of anti-TNF treatment should be carefully considered before initiation of Simponi therapy.
Pri bolnikih, ki so imeli že pred zdravljenjem demielinizirajočo bolezen oziroma se jim je ta pojavila pred kratkim, je treba skrbno pretehtati koristi in tveganja zdravljenja z zaviralci TNF, preden jim uvedete zdravljenje z zdravilom Simponi.
In patients with previous immune-mediated thrombocytopaenia from other parenteral GP IIb/IIIa inhibitors, there are no data with the use of INTEGRILIN.
Ni podatkov o uporabi zdravila INTEGRILIN pri bolnikih, ki so že imeli imunsko trombocitopenijo zaradi prejemanja drugih parenteralnih zaviralcev GP IIb/IIIa.
In patients with previous immune-mediated thrombocytopenia from other parenteral GP IIb/IIIa inhibitors, there are no data with the use of eptifibatide.
Ni podatkov o uporabi eptifibatida pri bolnikih, ki so že imeli imunsko trombocitopenijo zaradi prejemanja drugih parenteralnih zaviralcev GP IIb/IIIa.
In patients with previously untreated CLL receiving ofatumumab and chlorambucil, geometric mean CL and t½ values were 15.4 ml/h (range 4.1-146 ml/h) and 18.5 days (range 2.7-82.6 days) after the fourth infusion.
Pri bolnikih s predhodno nezdravljeno KLL, ki so dobivali ofatumumab in klorambucil, sta bili po četrti infuziji geometrična srednja vrednost CL 15,4 ml/uro (razpon: od 4,1 do 146 ml/uro) in t1/2 18,5 dni (razpon od 2,7 do 82,6 dni).
In patients with previously untreated CLL, the median decreases in B cell counts after the first cycle and prior to the sixth monthly cycle were 94% and >99% respectively for ofatumumab in combination with chlorambucil and 73% and 97% respectively for chlorambucil alone.
Bolnikom s predhodno nezdravljeno KLL, ki so prejemali kombinacijo ofatumumaba in klorambucila, se je število celic B po prvem ciklusu mediano zmanjšalo za 94 % in pred šestim mesečnim ciklusom za > 99 %; med prejemniki samega klorambucila sta bili zmanjšanji 73 % in 97 %.
In patients with prior chemotherapy a benefit was indicated in those with a KPS  80.
Pri bolnikih, ki so že prejemali kemoterapijo, so ugotavljali koristne učinke zdravila pri bolnikih z indeksom kliničnega stanja po Karnofskyju ≥ 80.
In patients with prolonged elevations of serum transaminases, it is appropriate to evaluate for other possible causes, such as infection, and referral to a specialist may be required.
Pri bolnikih s podaljšanim povišanjem serumskih transaminaz je treba oceniti druge možne vzroke, kot so okužbe, morda jih bo treba napotiti k specialistu.
In patients with pulmonary arterial hypertension, plasma concentrations of N-desmethyl metabolite are approximately 72 % those of sildenafil after 20 mg three times a day dosing (translating into a 36 % contribution to sildenafil’s pharmacological effects).
Pri bolnikih s pljučno arterijsko hipertenzijo je koncentracija N-dezmetilnega presnovka v plazmi približno 72 % koncentracije sildenafila po uporabi 20 mg trikrat na dan (kar pomeni 36 % prispevek k farmakološkim učinkom sildenafila).
In patients with pulmonary arterial hypertension, plasma concentrations of N-desmethyl metabolite are approximately 72 % those of sildenafil after 20 mg three times a day oral dosing (translating into a 36 % contribution to sildenafil’s pharmacological effects).
Pri bolnikih s pljučno arterijsko hipertenzijo je koncentracija N-dezmetilnega presnovka v plazmi približno 72 % koncentracije sildenafila po peroralni uporabi 20 mg trikrat na dan (kar pomeni 36 % prispevek k farmakološkim učinkom sildenafila).
In patients with pulmonary arterial hypertension, the average steady state concentrations were 20-50 % higher over the investigated oral dose range of 20–80 mg three times a day compared to healthy volunteers.
Pri bolnikih s pljučno arterijsko hipertenzijo je bila povprečna koncentracija v stanju dinamičnega ravnovesja v proučevanem območju peroralnega odmerka od 20 do 80 mg trikrat na dan od 20 do 50 % večja kot pri zdravih prostovoljcih.
In patients with pulmonary hypertension not receiving concomitant bosentan, the average tadalafil exposure at steady-state following 40 mg was 26 % higher when compared to those of healthy volunteers.
Povprečna biološka uporabnost tadalafila v ravnotežnem stanju po prejetju odmerka 40 mg je bila pri bolnikih, ki so sočasno prejemali bosentan, za 26 % višja v primerjavi z zdravimi prostovoljci.
In patients with reduced kidney function the dose of Xarelto may need to be adjusted.
Pri bolnikih s prizadetim delovanjem ledvic bo odmerek zdravila Xarelto morda treba prilagoditi.
In patients with refractory CLL, the median decrease in B cell counts was 22% after the first infusion and 92% at the eighth weekly infusion.
Pri bolnikih z neodzivno KLL se je število celic B po prvi infuziji mediano zmanjšalo za 22 % in ob osmi tedenski infuziji za 92 %.
In patients with relapsed/refractory CLL, the incidence of grade 3/4 hepatitis B infection (reactivation and primary infection) was 2% in R-FC vs 0% in FC.
Pri bolnikih s KLL, pri katerih se je bolezen ponovila oziroma so bili neodzivni na zdravljenje, je bila incidenca okužbe s hepatitisom B stopnje 3 ali 4 (reaktivacija in primarna okužba) 2 % pri R-FC v primerjavi z 0 % pri FC (fludarabinu in ciklofosfamidu).
In patients with relapsing remitting MS, Betaferon was more effective than placebo in reducing the number of annual relapses: patients receiving the medicine had on average 0.84 relapses a year, when patients on placebo had 1.27.
Pri bolnikih z recidivno-remitentno multiplo sklerozo je bilo zdravilo Betaferon pri zmanjševanju števila letnih recidivov učinkovitejše od placeba: bolniki, ki so prejemali zdravilo, so v povprečju doživeli 0,84 recidiva letno, bolniki, zdravljeni s placebom, pa 1,27.
In patients with relapsing remitting MS, Extavia was more effective than placebo in reducing the number of annual relapses: patients receiving the medicine had on average 0.84 relapses a year, when patients on placebo had 1.27 relapses.
Pri bolnikih z recidivno-remitentno multiplo sklerozo je bilo zdravilo Extavia pri zmanjševanju števila letnih recidivov učinkovitejše od placeba: bolniki, ki so prejemali zdravilo, so v povprečju doživeli 0,84 recidiva letno, bolniki, zdravljeni s placebom, pa 1,27.
In patients with renal angiomyolipoma, the kidney tumour shrank by at least half in 42% of patients (33 out of 79 patients) treated with Votubia, compared with none of the 39 patients who received placebo.
Pri bolnikih z ledvičnim angiomiolipomom se je ledvični tumor zmanjšal vsaj za polovico pri 42 % bolnikov (pri 33 bolnikih od 79), zdravljenih z zdravilom Votubia, medtem ko med 39 bolniki, ki so prejemali placebo, do tega ni prišlo pri nobenem bolniku.
In patients with renal disorders:
pri bolnikih z ledvičnimi motnjami:
In patients with renal failure or hepatic impairment, the pharmacokinetics of granisetron were determined following a single 40 g/kg intravenous dose of granisetron hydrochloride.
Pri bolnikih z odpovedjo ledvic ali okvaro jeter so farmakokinetiko granisetrona ugotavljali po enem samem intravenskem odmerku 40 µg/kg granisetronijevega klorida.
In patients with renal impairment accumulation occurs relative to the degree of impairment.
Pri bolnikih z okvaro ledvic se učinkovina kopiči sorazmerno s stopnjo okvare.
In patients with renal impairment in whom Mycophenolate mofetil Teva and ganciclovir or its prodrugs, e.g. valganciclovir, are co-administered the dose recommendations for ganciclovir should be observed and patients monitored carefully.
Bolnike z ledvično okvaro, ki sočasno dobivajo zdravilo mofetilmikofenolat in ganciklovir oziroma njegova predzdravila, npr. valganciklovir, je treba skrbno nadzorovati in proučiti odmerjanje ganciklovirja.
In patients with renal impairment in whom Myfenax and ganciclovir or its prodrugs, e.g. valganciclovir, are co-administered the dose recommendations for ganciclovir should be observed and patients monitored carefully.
Bolnike z ledvično okvaro, ki sočasno dobivajo zdravilo mofetilmikofenolat in ganciklovir oziroma njegova predzdravila, npr. valganciklovir, je treba skrbno nadzorovati in proučiti odmerjanje ganciklovirja.
In patients with renal impairment, increased exposure to enoxaparin sodium is associated with an increased risk of bleeding.
Ker so bolniki z ledvično okvaro bolj izpostavljeni natrijevemu enoksaparinatu, je pri njih povečano tveganje za krvavitev.
In patients with renal impairment, insulin requirements may be diminished due to reduced insulin metabolism.
Pri bolnikih z okvaro ledvic se lahko potreba po insulinu zaradi zmanjšane presnove insulina zmanjša.
In patients with renal impairment, the maximum daily dose should be 18 mg.
Pri bolnikih z okvaro ledvic je največji dnevni odmerek 18 mg.
In patients with renal or hepatic impairment, co- administration of colchicine in patients on Aptivus/ritonavir is contraindicated (see section 4.3).
Za zdravljenje bolnikov z ledvično ali jetrno okvaro, ki jemljejo zdravilo Aptivus/ritonavir, je sočasna uporaba kolhicina kontraindicirana (glejte poglavje 4.3).
In patients with renal or hepatic impairment, co-administration of colchicine in patients on Aptivus/ritonavir is contraindicated (see section 4.3).
Za zdravljenje bolnikov z ledvično ali jetrno okvaro, ki jemljejo zdravilo Aptivus/ritonavir, je sočasna uporaba kolhicina kontraindicirana (glejte poglavje 4.3).
In patients with renal risk factors, the co-administration of tenofovir disoproxil fumarate with a boosted protease inhibitor should be carefully evaluated.
Pri bolnikih z dejavniki tveganja za ledvice je treba sočasno dajanje dizoproksiltenofovirijevega fumarata z okrepljenimi zaviralci proteaze skrbno oceniti.
In patients with rheumatoid arthritis, premedication with 100 mg intravenous methylprednisolone should be completed 30 minutes prior to MabThera infusions to decrease the incidence and severity of infusion related reactions (IRRs).
Pri bolnikih z revmatoidnim artritisom je treba 30 minut pred pričetkom infundiranja zdravila MabThera zaključiti z intravenskim dajanjem 100 mg metilprednizolona za zmanjšanje incidence in resnosti reakcij, povezanih z infuzijo.
In patients with SCN
Bolniki s hudo kronično nevtropenijo
In patients with secondary hyperparathyroidism Renagel should be used within the context of a multiple therapeutic approach, which could include calcium supplements, 1,25-dihydroxy Vitamin D3 or one of its analogues to lower the intact parathyroid hormone (iPTH) levels.
Pri bolnikih s sekundarnim hiperparatiroidizmom je treba zdravilo Renagel uporabljati v smislu večstranskega pristopa zdravljenja, ki lahko vključuje kalcijeve dodatke, 1,25 – dihidroksi vitamin D3 ali kakšen njegov analog, za znižanje koncentracije intaktnega paratiroidnega hormona (iPTH).
In patients with secondary hyperparathyroidism Renagel should be used within the context of a multiple therapeutic approach, which could include calcium supplements, 1,25-dihydroxy Vitamin D3 or one of its analogues to lower the iPTH levels.
Pri bolnikih s sekundarnim hiperparatiroidizmom je treba zdravilo Renagel uporabljati v smislu večstranskega pristopa zdravljenja, ki lahko vključuje kalcijeve dodatke, 1,25 – dihidroksi vitamin D3 ali kakšen njegov analog, za znižanje koncentracijeiPTH.
In patients with secondary hyperparathyroidism Renvela should be used within the context of a multiple therapeutic approach, which could include calcium as supplements, 1,25 - dihydroxy Vitamin D3 or one of its analogues to lower the intact parathyroid hormone (iPTH) levels.
Pri bolnikih s sekundarnim hiperparatiroidizmom je treba zdravilo Renvela uporabljati v smislu večstranskega pristopa zdravljenja, ki lahko vključuje kalcij kot dodatke, 1,25 - dihidroksi vitamin D3 ali kakšen njegov analog za nižanje ravni intaktnega paratiroidnega hormona (iPTH).
In patients with secondary hyperparathyroidism Renvela should be used within the context of a multiple therapeutic approach, which could include calcium as supplements, 1,25 – dihydroxy Vitamin D3 or one of its analogues to lower the intact parathyroid hormone (iPTH) levels.
Pri bolnikih s sekundarnim hiperparatiroidizmom je treba zdravilo Renvela uporabljati v smislu večstranskega pristopa zdravljenja, ki lahko vključuje kalcij kot dodatke, 1,25 - dihidroksi vitamin D3 ali kakšen njegov analog za nižanje ravni intaktnega paratiroidnega hormona (iPTH).
In patients with secondary hyperparathyroidism Sevelamer carbonate Zentiva should be used within the context of a multiple therapeutic approach, which could include calcium as supplements, 1,25 - dihydroxy Vitamin D3 or one of its analogues to lower the intact parathyroid hormone (iPTH) levels.
Pri bolnikih s sekundarnim hiperparatiroidizmom je treba zdravilo Sevelamer carbonate Zentiva uporabljati v smislu večstranskega pristopa zdravljenja, ki lahko vključuje kalcij kot dodatke, 1,25 - dihidroksi vitamin D3 ali kakšen njegov analog za nižanje ravni intaktnega paratiroidnega hormona (iPTH).
In patients with secondary hyperparathyroidism sevelamer hydrochloride should be used within the context of a multiple therapeutic approach, which could include calcium supplements, 1,25-dihydroxy Vitamin D3 or one of its analogues to lower the intact parathyroid hormone (iPTH) levels.
Pri bolnikih s sekundarnim hiperparatiroidizmom je treba sevelamerijev klorid uporabljati v smislu večstranskega pristopa zdravljenja, ki lahko vključuje kalcijeve dodatke, 1,25 – dihidroksi vitamin D3 ali kakšen njegov analog, za znižanje koncentracije intaktnega paratiroidnega hormona (iPTH).
In patients with secondary hyperparathyroidism sevelamer hydrochloride should be used within the context of a multiple therapeutic approach, which could include calcium supplements, 1,25-dihydroxy Vitamin D3 or one of its analogues to lower the iPTH levels.
Pri bolnikih s sekundarnim hiperparatiroidizmom je treba sevelamerijev klorid uporabljati v smislu večstranskega pristopa zdravljenja, ki lahko vključuje kalcijeve dodatke, 1,25 – dihidroksi vitamin D3 ali kakšen njegov analog, za znižanje koncentracije iPTH.
In patients with SEGA, everolimus Cmin was approximately dose-proportional within the dose range from 1.35 mg/m2 to 14.4 mg/m2.
Pri bolnikih s SEGA je bila Cmin everolimusa približno sorazmerna z višino odmerka v okviru odmerjanja od 1,35 mg/m2 do 14,4 mg/m2.
In patients with severe (Child-Pugh C) hepatic impairment, the recommended starting dose is 14 mg taken once daily.
Pri bolnikih s hudo (Child-Pugh C) okvaro jeter je priporočeni začetni odmerek 14 mg enkrat na dan.
In patients with severe chronic neutropenia (SCN)
Pri bolnikih s hudo kronično nevtropenijo
In patients with severe chronic neutropenia (SCN)
Pri bolnikih s hudo kronično nevtropenijo (SCN – »severe chronic neutropenia«)
In patients with severe chronic neutropenia (SCN) Congenital neutropenia
Pri bolnikih s hudo kronično nevtropenijo Prirojena nevtropenija
In patients with severe hepatic impairment (Child-Pugh class C), fingolimod- phosphate Cmax was decreased by 22% and AUC was not substantially changed.
Pri bolnikih s hudo okvaro jeter (Child-Pugh stopnje C) se je Cmax fingolimodijevega fosfata znižala za 22 %, AUC pa se ni bistveno spremenila.
In patients with severe hepatic impairment,
Pri bolnikih s hudo jetrno okvaro.
In patients with severe hepatic impairment, insulin requirements may be diminished due to reduced capacity for gluconeogenesis and reduced insulin metabolism.
Bolnikom s hudo okvaro jeter se lahko potreba po insulinu zmanjša zaradi zmanjšane zmožnosti za glukoneogenezo in zmanjšane presnove insulina.
In patients with severe hepatic impairment, it is recommended that the maintenance dose of Rapamune be reduced by approximately one-half.
Pri bolnikih s hudo jetrno okvaro je priporočljivo zmanjšati vzdrževalni odmerek zdravila Rapamune za približno polovico.
In patients with severe hepatic impairment, monitoring should be performed every 5 to 7 days until 3 consecutive trough levels have shown stable concentrations of sirolimus after dose adjustment or after loading dose due to the delay in reaching steady-state because of the prolonged half-life.
Pri bolnikih s hudo jetrno okvaro naj se spremljanje opravi vsakih 5 do 7 dni, dokler 3 zaporedne najnižje koncentracije v stanju dinamičnega ravnovesja ne pokažejo stabilnih koncentracij sirolimusa po prilagoditvi odmerka ali po polnitvenem odmerku, ker se stanje dinamičnega ravnovesja, zaradi podaljšanja razpolovnega časa, doseže pozneje.
In patients with severe hepatic impairment, reduction in maintenance dose by one half is recommended based on decreased clearance (see sections 4.2 and 5.2).
Pri bolnikih s hudo jetrno okvaro na podlagi zmanjšanja očistka priporočamo zmanjšanje vzdrževalnega odmerka za polovico (glejte poglavji 4.2 in 5.2).
In patients with severe hepatic impairment, reduction in maintenance dose by one-half is recommended based on decreased clearance (see sections 4.2 and 5.2).
Pri bolnikih s hudo jetrno okvaro na podlagi zmanjšanja očistka priporočamo zmanjšanje vzdrževalnega odmerka za polovico (glejte poglavji 4.2 in 5.2).
In patients with severe hepatic impairment.
Pri bolnikih s hudo jetrno okvaro.
In patients with severe hypertension (SBP ≥180 mmHg), the reduction in blood pressure from baseline for Rasitrio and the dual combinations respectively was 49.5/22.5 mmHg compared to 38.1/17.6 mmHg with aliskiren/amlodipine combination (300/10 mg), 33.2/14.3 mmHg with aliskiren/hydrochlorothiazide (300/25 mg) and 39.9/17.8 mmHg with amlodipine/hydrochlorothiazide (10/25 mg).
≥180 mmHg) je zdravilo Rasitrio znižalo krvni tlak od izhodiščnih vrednosti za 49,5/22,5 mmHg v primerjavi z znižanjem za 38,1/17,6 mmHg pri uporabi kombinacije aliskirena/amlodipina (300/10 mg), za 33,2/14,3 mmHg pri uporabi kombinacije aliskirena/hidroklorotiazida (300/25 mg) in za 39,9/17,8 mmHg pri uporabi kombinacije amlodipina/hidroklorotiazida (10/25 mg).
In patients with severe kidney problems or who are likely to develop fluid retention, treatment should start with the lowest dose and the patient’s kidneys should be monitored closely.
Pri bolnikih s hudo okvaro ledvic ali tistih, nagnjenih k zastajanju tekočine, je treba zdravljenje začeti z najnižjim odmerkom, pri čemer je treba skrbno spremljati delovanje bolnikovih ledvic.
In patients with severe leukopenia, neutropenia, or thrombocytopenia,
Pri bolnikih s hudo levkopenijo, nevtropenijo ali trombocitopenijo.
In patients with severe leukopenia, neutropenia, or thrombocytopenia.
Pri bolnikih s hudo levkopenijo, nevtropenijo ali trombocitopenijo.
In patients with severe renal impairment (20 mL/min  CrCl  40 mL/min) the recommended dose is 250 mg/m² every 3 weeks (see section 5.2).
Za bolnike s hudo okvaro ledvic (20 ml/min  OK < 60 ml/min) je priporočeni odmerek 250 mg/m² vsake 3 tedne (glejte poglavje 5.2).
In patients with severe renal impairment (CLCR ≤30 ml/min) and in patients with endstage renal disease, a maximum maintenance dose of 250 mg/day is recommended.
Pri bolnikih s hudo ledvično okvaro (CLCR ≤ 30 ml/min) in pri bolnikih s končno ledvično odpovedjo je priporočeni največji vdrževalni odmerek 250 mg/dan.
In patients with severe renal impairment (CLCR ≤30 ml/min) and in patients with endstage renal disease, a maximum maintenance dose of 250 mg/day is recommended.
Pri bolnikih s hudo ledvično okvaro (CLCR ≤ 30 ml/min) in pri bolnikih s končno ledvično odpovedjo je priporočeni največji vzdrževalni odmerek 250 mg/dan.
In patients with severe renal impairment (CLCR ≤30 ml/min) and in patients with endstage renal disease, a maximum maintenance dose of 250 mg/day is recommended..
Pri bolnikih s hudo ledvično okvaro (CLCR ≤ 30 ml/min) in pri bolnikih s končno ledvično odpovedjo je priporočeni največji vzdrževalni odmerek 250 mg/dan.
In patients with severe renal impairment (CLCR ≤30 ml/min) and in patients with endstage renal disease,a maximum maintenance dose of 250 mg/day is recommended.
Pri bolnikih s hudo ledvično okvaro (CLCR ≤ 30 ml/min) in pri bolnikih s končno ledvično odpovedjo je priporočeni največji vzdrževalni odmerek 250 mg/dan.
In patients with severe renal impairment (CrCl < 30 ml/min), the dose of doripenem should be 250 mg every 12 hours (see section 6.6).
250 mg na 8 ur (glejte poglavje 6.6), pri bolnikih s hudo okvaro ledvic (CrCl < 30 ml/min) pa 250 mg na 12 ur (glejte poglavje 6.6).
In patients with severe renal impairment (CrCL <30 mL/min, calculated by the Cockroft-Gault formula), the recommended dose of bosutinib is 300 mg daily (see sections 4.4 and 5.2).
Pri bolnikih s hudo okvaro ledvic (CrCL < 30 ml/min, izračunan po Cockroft-Gaultovi formuli) je priporočeni odmerek bosutiniba 300 mg na dan (glejte poglavji 4.4 in 5.2).
In patients with severe renal impairment (creatinine clearance 15–30 mL/min), plasma concentrations of bosentan decreased by approximately 10%.
Pri bolnikih s hudo okvarjenim delovanjem ledvic (očistek kreatinina 15–30 ml/min) so se plazemske koncentracije bosentana znižale za približno 10 %.
In patients with severe renal impairment (creatinine clearance 5 – 29 ml/min) daily dose should be 10 mg (1 ml solution, equivalent to two pump actuations) per day.
Pri bolnikih s hudo okvaro delovanja ledvic (očistek kreatinina 5-29 ml/min) naj bo dnevni odmerek 10 mg (1 ml raztopine, kar ustreza dvema pritiskoma navzdol).
In patients with severe renal impairment (creatinine clearance 5 – 29 ml/min) daily dose should be 10 mg per day.
Pri bolnikih s hudo okvaro delovanja ledvic (očistek kreatinina 5 – 29 ml/min) naj bo dnevni odmerek 10 mg na dan.
In patients with severe renal impairment (creatinine clearance 5 – 29 ml/min) daily dose should be 10 mg per day.
Pri bolnikih s hudo okvaro delovanja ledvic (očistek kreatinina 5 – 29 ml/min) naj bo dnevni odmerek 10 mg.
In patients with severe renal impairment (creatinine clearance 5 – 29 ml/min) daily dose should be 10 mg per day.
Pri bolnikih s hudo okvaro ledvičnega delovanja (kreatininski očistek 5 − 29 ml/min) naj bo dnevni odmerek 10 mg.
In patients with severe renal impairment (creatinine clearance 5 – 29 ml/min) daily dose should be 10 mg per day.
Pri bolnikih s hudo okvaro ledvičnega delovanja (kreatininski očistek 5–29 ml/min) naj bo dnevni odmerek 10 mg.
In patients with severe renal impairment (creatinine clearance 5-29 ml/min) daily dose should be 10 mg per day.
Pri bolnikih s hudo okvaro delovanja ledvic (očistek kreatinina 5 – 29 ml/min) naj bo dnevni odmerek 10 mg.
In patients with severe renal impairment (creatinine clearance 5-29 ml/min) daily dose should be 10 mg per day.
Pri bolnikih s hudo okvaro delovanja ledvic (očistek kreatinina 5–29 ml/min) naj bo dnevni odmerek 10 mg.